S3 Table. Characteristics of patients with/without Confirmatory Bone scan who had PSA response ≥ 6 months

	Without confirmatory BS (n=27)	With confirmatory BS (n=32)	p-value
Age (yr)	71.8±7.2	68.3±7.8	0.086
BMI (kg/m^2)	25.3±3.1	24.6±2.6	0.446
PSA (pre-treatment) (ng/dL)	74.6 (16.4-132.5)	64.9 (13.3-313.0)	0.927
ECOG score 0-1	22 (71.5)	30 (93.7)	0.229
HTN	11 (40.7)	11 (34.4)	0.815
DM	4 (14.8)	6 (18.8)	0.741
Cardiovascular disease	4 (14.8)	3 (9.4)	0.692
Primary treatment			
Radical prostatectomy	7 (25.9)	7 (21.9)	0.716
Radiotherapy	7 (25.9)	13 (40.6)	0.235
Timing of Enzalutamide			0.535
Pre-docetaxel	13 (48.1)	18 (56.3)	
Post-docetaxel	14 (51.9)	14 (43.8)	
Metastasis type			
Bone metastasis only	18 (81.8)	26 (96.3)	0.160
Visceral metastasis only	0 (0.0)	1 (3.2)	> 0.99
Both bone and visceral metastasis	3 (12.0)	4 (12.9)	> 0.99
No. of bone metastases			0.267
< 10	14 (66.7)	13 (50.0)	
10-20	4 (19.0)	11 (42.3)	
> 20	3 (14.3)	2 (7.7)	
ISUP GG			0.513
1-3	3 (13.6)	6 (20.7)	
4-5	19 (86.4)	31 (79.3)	
Cycle of enzalutamide	8.5±3.9	17.9±14.4	0.001

Values are presented as mean±SD, median (IQR), or number (%). BMI, body mass index; DM, diabetes mellitus; ECOG, Eastern Cooperative Oncology Group; HTN, hypertension; IQR, interquartile range; ISUP GG, International Society of Urological Pathology Grade Group; PSA, prostate-specific antigen; SD, standard deviation.